UCB stock: Company reports new immunology data from EADV and AANEM meetings
Published on 10/06/2026 at 17:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB reported new clinical data from its immunology portfolio at scientific meetings held in late September and early October. The Belgian biopharmaceutical company is listed on Euronext Brussels under the symbol UCB.
New hidradenitis suppurativa data
In a September 30, 2026 release, UCB said data presented at the 2026 European Academy of Dermatology and Venereology Congress supported earlier use of BIMZELX (bimekizumab) in moderate-to-severe hidradenitis suppurativa. UCB reported that 47.4% of patients in the shortest disease-duration group achieved complete resolution of inflammatory lesions after three years, compared with 33.3% in the longest-duration group.
The company also reported that 67.3% of biologic-naive patients achieved complete resolution of draining tunnels at three years. In a one-year analysis, 30.7% of patients receiving bimekizumab were free of all tunnels, according to UCB.
Myasthenia gravis research
UCB said in a September 29, 2026 release that it presented data at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting and the Myasthenia Gravis Foundation of America scientific session. The company highlighted analyses involving minimal symptom expression in generalized myasthenia gravis, patient perspectives on ocular symptoms and social-risk screening.
The release also described interim Phase 1b data for cizutamig, an investigational BCMA-by-CD3 T-cell engager. UCB said the candidate is not approved by the U.S. Food and Drug Administration or any health authority.
